Composition
Inj: Vial containing 20 mg of daunorubicin HCI as powder, and vial containing 10 ml of saline solution.
Indications & Dosage
Acute myelogenous leukaemia, Acute lymphocytic Leukaemia, Advanced AIDS-related Kaposis sarcoma: BY IV INF: Adults: 0.8 mg/kg continue with a maintenance dose of 0.8-1 mg/kg; max 25 mg/kg. (consult product literature). Children: Initial dose of 1 mg/kg of daunomycin daily for 4-5 days, max 25 mg/kg. (consult product literature).
Administration
Never administer IM or SC. Administer IVP over 1-5 min into the tubing of a rapidly infusing IV solution of D5W or NS; Daunorubicin has also been diluted in 100 ml of D5W or NS and infused over 15-30 min. Dilute vials with 4 ml SWFI for a final concentration of 5 mg/ml.
Compatibility
Stable in D5W, LR, NS, SWFI.
Contraindications
Myocardial insufficiency, previous treatment with maximum cumulative doses of daunorubicin or other anthracycline, recent myocardial infarction, severe arrhythmia, severe renal or hepatic impairment.
Precautions
Renal and hepatic impairment, Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility. Cardiac function should be monitored closely.
Interactions
BCG; clozapine; natalizumab; pimecrolimus; tacrolimus (topical); live vaccines (avoid), leflunomide, roflumilast, trastuzumab.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast feeding
Side Effects
A lopecia,bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumourlysis syndrome, vomiting, cardiotoxicity